Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.

The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.

BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.

The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.

BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.

Shares of Erasca were up 2.9% in Thursday trading.

Price: 13.49, Change: +0.31, Percent Change: +2.35